Table 2.
Response rate |
PFS |
OS |
||||
---|---|---|---|---|---|---|
N | OR (95% CI) | N | HR (95% CI) | N | HR (95% CI) | |
Overall P-value |
88 | 1.61 (1.40–1.84) <0.001 |
71 | 0.75 (0.69–0.81) <0.001 |
48 | 0.87 (0.81–0.94) <0.001 |
Class of backbone drug Targeted small molecule inhibitors Targeted monoclonal antibodies Immunotherapy Hormonal Not classifiedb |
33 12 9 31 3 |
1.31 (1.07–1.61) p = .01 2.17 (1.55–3.02) p < .001 2.13 (1.38–3.28) p < .001 1.54 (1.27–1.87) p < .001 4.71 (1.90–11.67) p = .001 |
29 12 3 25 2 |
0.90 (0,59–1.36)p = .60 0.87 (0.53–1.44) p = .59 0.64 (0.36–1.12) p = .11 0.69 (0.61–0.78) p < .001 1.32 (0.82–2.14) p = .25 |
24 8 3 11 2 |
0.82 (0.57–1.17) p = .26 0.57 (0.38–0.85) p = .007 0.49 (0.33–0.74) p = .001 0.95 (0.78–1.17) p = .65 1.61 (0.97–2.65) p = .06 |
Tumor Type Breast Cancer Colorectal Cancer NSCLC Prostate Cancer RCC Others |
28 5 21 6 12 16 |
NS NS NS NS NS NS |
24 4 20 5 10 8 |
0.90 (0.59–1.36) p = .60 0.83 (0.56–1.24) p = .36 0.83 (0.73–0.94) 0.005 0.50 (0.29–0.86) p = .01 0.82 (0.64–1.05) p = .11 0.92 (0.72–1.18) p = .50 |
9 4 18 6 7 4 |
0.82 (0.57–1.17) p = .26 1.55 (0.94–2.56) p = .08 1.32 (1.01–1.71) p = .04 0.54 (0.38–0.77) p = .001 1.27 (1.02–1.59) 0.035 0.98 (0.83–1.14) p = .75 |
Median Number Prior Regimensc 0 1 2 3 or more |
35 35 11 5 |
NS NS NS NS |
33 27 9 2 |
NS NS NS NS |
19 19 8 2 |
0.82 (0.57–1.17) p = .26 0.59 (0.40–0.87) p = .008 0.70 (0.45–1.07) p = .09 0.76 (0.58–0.99) p = .04 |
aSingle agents are the reference point for all statistics. The final model included the following variables in each category: RR (Backbone drug class and linear start of enrollment year); OS (backbone drug class, tumor indication, and median prior regimens); PFS (backbone drug class and tumor indication).
bNot Classified included: prednisone, lenalidomide, cimetidine, retinoic acid, simvastatin, zoledronic acid, alendronate, sargramostim. For a full list of classification of agents see Supplemental Table 1.
cTwo trials included in response rate analysis did not reported number of prior regimens.
Abbreviations: HR, hazard ratio; mAB: monoclonal antibody; N, number of randomized comparisons included; NS: not significant in (and therefore not included in) multivariate model; NSCLC: non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; OR, odds ratio; RCC: renal cell carcinoma.